ReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia

Singapore Medical Journal

Volumn 46, Issue 8, 2005, Pages 407-413

  Poh, Kian Keong ^a   Tan, H C ^a   Yip, J W L ^a   Lim, Y T ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Abciximab; Adjuvant drug therapy; Angioplasty; Coronary disease; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; HEPARIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INDIA; KOREA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTICENTER STUDY; PAKISTAN; PERCUTANEOUS CORONARY INTERVENTION; PHILIPPINES; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SINGAPORE; THAILAND; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASIA; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RISK FACTORS;

EID: 23244445722     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gruentzig AR, King SB 3rd, Schlumpf M, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 1987; 316:1127-32.
2. Parisi AF, Holland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992; 326:10-6.
3. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19:926-35.
4. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82:739-50.
5. Ellis SG, Bates ER, Schaible T, et al. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17(6suppl B):89B-95B.
6. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-9.
7. Adgey AA. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998; 135:843-55.
8. Nguyen CM, Harrington RA. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs 2003; 3:423-36.
9. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41:26-32.
10. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001; 37:2059-65.
11. Ibbotson T, McGavin JK, Goa KL. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Am J Cardiovasc Drugs 2003; 3:381-6.
12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956-61.
13. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689-96.
14. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352:87-92.
15. Tan HC, Lim YT, Lim TT, et al. The use of abciximab in coronary angioplasty - an Asian centre's experience. Singapore Med J 2000; 41:69-73.
16. Huber K. The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics. J Thromb Thrombolysis 2003; 15:99-103.
17. Sim DS, Jeong MH, Kim W, et al. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention. Korean J Intern Med 2003; 18:129-37.
18. Price DJ, Campbell PG, Sutton AG, et al. Selective use of abciximab in coronary stenting: overall outcomes can still be equivalent to those in the EPISTENT treatment group. Int J Cardiovasc Intervent 2001; 4:15-20.
19. Cote AV, Berger PB, Holmes DR Jr, et al. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 2001; 76:890-6.
20. Fahdi IE, Saucedo JF, Hennebry T, et al. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93:453-5.
21. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997; 79:286-91.
22. Ross MJ, Herrmann HC, Moliterno DJ, et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol 2003; 42:981-8.
23. Tamburino C, Russo G, Nicosia A, et al. Prophylactic abciximab in elective coronary stenting: results of a randomized trial. J Invasive Cardiol 2002; 14:72-9.
24. Velianou JL, Strauss BH, Kreatsoulas C, et al. Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: in-hospital and six-month outcomes. Catheter Cardiovasc Interv 2000; 51:138-44.
25. Fuchs S, Kornowski R, Mehran R, et al. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty. J Invasive Cardiol 2000; 12:497-501.
26. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113:1-6.
27. Wijpkema JS, Jessurun GA, Van Boven AJ, et al. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Catheter Cardiovasc Interv 2003; 60:339-43.